SCHEMBL1075702

SCHEMBL1075702

CCCC(O)=C(C)C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 4/20 0.43
HDAC1 Q13547 4/20 0.43
HDAC2 Q92769 4/20 0.43
HDAC8 Q9BY41 4/20 0.43
FFAR3 O14843 3/20 0.43
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
CTSD P07339 1/20 0.37
TSHR P16473 4/20 0.36
ALDH1A1 P00352 3/20 0.35
THRB P10828 1/20 0.34
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34
PGGT1B P53609 1/20 0.34
TDP1 Q9NUW8 3/20 0.33
ALOX15 P16050 2/20 0.33
AKR1B1 P15121 1/20 0.33
LMNA P02545 1/20 0.33
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL45044 1.00 HDAC3 (0.43) HDAC3HDAC1HDAC2HDAC8FFAR3
SCHEMBL444337 0.86 CES1 (0.44) CES2CES1TSHRALDH1A1THRB
SCHEMBL4593133 0.86 CES1 (0.44) CES2CES1TSHRALDH1A1THRB
Phenol SCHEMBL1415085 0.83 HSD17B3 (0.42) CES2CES1ALDH1A1TDP1LMNA
Phenol SCHEMBL45542 0.83 HSD17B3 (0.42) CES2CES1ALDH1A1TDP1LMNA
SCHEMBL27920516 0.82 GPR84 (0.52) CES2CES1TSHRALDH1A1THRB
SCHEMBL11783133 0.79 HDAC3 (0.48) HDAC3HDAC1HDAC2HDAC8FFAR3
SCHEMBL16664 0.79 HDAC3 (0.48) HDAC3HDAC1HDAC2HDAC8FFAR3
SCHEMBL671878 0.79
SCHEMBL2350817 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2777723-B1 Implantable object comprising selectively degradable copolymers for improved explantability BIOTRONIK AG (CH) 2017-12-20 EP claimed
EP-2136851-B1 A COATING OF FAST ABSORPTION OR DISSOLUTION ABBOTT CARDIOVASCULAR SYSTEMS INC (US) 2017-09-06 EP claimed
US-20140079742-A1 COATING OF FAST ABSORPTION OR DISSOLUTION ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) 2014-03-20 US claimed
US-20140074224-A1 COATING OF FAST ABSORPTION OR DISSOLUTION ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) 2014-03-13 US claimed
EP-2136851-A2 A COATING OF FAST ABSORPTION OR DISSOLUTION Abbott Cardiovascular Systems, Inc. (US) 2009-12-30 EP claimed
WO-2008076731-A2 A COATING OF FAST ABSORPTION OR DISSOLUTION ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) 2008-06-26 WO claimed
US-20080145393-A1 Coating of fast absorption or dissolution ADVANCED CARDIOVASCULAR SYSTEMS, INC. 2008-06-19 US claimed
WO-1993023570-A1 OLIGONUCLEOTIDES HAVING CONJUGATES ATTACHED AT THE 2'-POSITION OF THE SUGAR MOIETY PHARMAGENICS, INC. (US) 1993-11-25 WO claimed
CN-117396497-A Use of long acting growth hormone for the treatment of inflammation induced diseases 阿森迪斯药物股份有限公司 2024-01-12 CN disclosed
CN-109843295-B Combination therapy with controlled release of CNP agonist 阿森迪斯药物生长障碍股份有限公司 2022-04-05 CN disclosed
CN-107405409-B CNP prodrugs 阿森迪斯药物生长障碍股份有限公司 2022-03-22 CN disclosed
EP-3873904-A1 TETRAHYDROPYRAN (THP)-SUBSTITUTED BICYCLIC-PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. (US) 2021-09-08 EP disclosed
EP-3755311-A2 INDANE-AMINES AS PD-L1 ANTAGONISTS ChemoCentryx, Inc. (US) 2020-12-30 EP disclosed
WO-2020168172-A1 CONJUGATE COMPOUNDS FOR THE DEGRADATION OF RAF ZAMBONI CHEM SOLUTIONS INC. (CA) 2020-08-20 WO disclosed
US-5607659-A Directed biodistribution of radiolabelled biotin using carbohydrate polymers NEORX CORPORATION (US) 1997-03-04 US disclosed
WO-1996033199-A1 PROCESS FOR MAKING 1-HYDROXYBISPHOSPHONATES MERCK & CO., INC. (US) 1996-10-24 WO disclosed
EP-0683676-A1 DIRECTED BIODISTRIBUTION OF SMALL MOLECULES NEORX CORPORATION (US) 1995-11-29 EP disclosed
EP-0646019-A1 PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1995-04-05 EP disclosed
WO-1994017829-A1 DIRECTED BIODISTRIBUTION OF SMALL MOLECULES NEORX CORPORATION (US) 1994-08-18 WO disclosed
WO-1993025240-A2 PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1993-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080145393-A1 Coating of fast absorption or dissolution TNNC1, SLC10A2, SI HDAC3 2596/4885HDAC1 1567/4885HDAC2 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.